Overview of Enalapril Mylan

Quick Facts

Property	Description
Active ingredient	Enalapril maleate
Form	Tablet (oral)
Pharmacological class	Angiotensin-Converting Enzyme (ACE) Inhibitor
Common purpose	Modifies blood pressure regulation
Origin	Synthetic compound

What Kind of Medicine is Enalapril Mylan?

Enalapril Mylan is a prescription-only medicine that utilizes the synthetic compound Enalapril maleate as its active ingredient, delivered in a tablet form for oral administration. The drug entity, Enalapril, belongs to a crucial class of cardiovascular agents known as Angiotensin-Converting Enzyme (ACE) Inhibitors. As a generic product, Enalapril Mylan is distinguished by being supplied under the Mylan brand, ensuring standardized manufacturing processes. The maleate salt form is specifically chosen for its physical properties and consistent therapeutic delivery, and Enalapril itself is categorized as a prodrug because it converts into its highly active metabolite, enalaprilat, within the body to exert its therapeutic effect.

Enalapril Mylan's Pharmacological Role

The general purpose of Enalapril Mylan is to support cardiovascular function by modulating the system responsible for blood vessel tone. Its function as an ACE Inhibitor is achieved by blocking the Angiotensin-Converting Enzyme from producing the potent vasoconstrictor Angiotensin II. This targeted intervention is clinically recognized for effectively managing systemic vascular resistance. Suppression of this step within the Renin-Angiotensin-Aldosterone System (RAAS) facilitates generalized vasodilation, causing blood vessels to relax and widen. The resulting reduction in vascular resistance is the fundamental physiological effect, promoting more efficient cardiac function.

Regulatory References

StatPearls NCBI

What side effects are possible with Enalapril Mylan?

Enalapril Mylan's safety profile is documented in government regulatory labels using a classification system that groups adverse reactions by their documented frequency (e.g., Very Common, Common, Uncommon, Rare) and the affected System-Organ Class (SOC).

Adverse Reaction Classifications

The most frequently documented side effects include cough, dizziness, blurred vision, and asthenia (weakness), which are listed as Very Common (ge 1/10) in official sources. Common effects (> 1/100, < 1/10) include headache, fatigue, hypotension (low blood pressure), nausea, diarrhoea, and documented increases in serum creatinine and hyperkalaemia.

Serious Adverse Reactions

Official labels explicitly highlight the risk of serious adverse reactions, most notably Angioedema (swelling of the face, extremities, lips, tongue, glottis, and/or larynx), which is documented as potentially fatal and may occur at any time during treatment. Other serious documented risks include Fetal Toxicity, where use during the second and third trimesters of pregnancy is associated with injury and death to the developing fetus, and rare instances of hepatic failure.

Population-Specific Safety Constraints

The regulatory profile defines constraints for specific patient populations. Use is contraindicated in the second and third trimesters of pregnancy due to the risk of fetal injury. Patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are noted to be at an increased risk of severe hypotension and renal insufficiency. Furthermore, symptomatic hypotension is noted as being most likely to occur at the initiation of treatment.

Regulatory Safety Summary

The official documents structure the safety profile by clearly defining the expected incidence and systemic impact of documented adverse reactions. This classification allows for the explicit highlighting of serious, low-incidence risks and the mandatory constraints for high-risk populations, establishing the comprehensive range of known safety characteristics without providing clinical advice or treatment interpretations.

Overdose and Emergency Response

Overdose and when to seek help

This information is based strictly on official regulatory overdose and emergency documentation for Enalapril maleate.

Domain	Official Regulatory Statement
Documented Overdose Manifestations	The primary presentation of overdose is profound systemic hypotension (excessive blood pressure drop), which may be accompanied by dizziness, lightheadedness, fainting (syncope), tachycardia, or bradycardia.
Physiological Systems Affected	Cardiovascular (hypotension, rhythm changes); Renal (acute renal failure); Central Nervous System (stupor/somnolence).
Population-specific Notes	Patients who are volume-depleted are at an elevated risk of excessive hypotension following overexposure. Impaired renal function prolongs the half-life of the active substance.
Emergency-response Statements	Immediate management includes placing the patient in the supine position and, if needed for hypotension, administering an intravenous infusion of normal saline for volume expansion. The active metabolite, Enalaprilat, is dialyzable.

Official Overdose Statements

The most likely clinical manifestation of an overdose is profound hypotension, which may progress to documented severe outcomes, including circulatory shock and acute renal failure.
Immediate medical attention must be sought for any signs of overdose or symptoms of profound hypotension.
Urgent help is required if the individual presents with severe symptoms such as collapse, seizure, trouble breathing, or unconsciousness.
There is no specific antidote known; treatment remains strictly symptomatic and supportive, as detailed in regulatory documents.

The regulatory profile defines the overdose risk through the primary physiological consequence of excessive ACE inhibition—profound systemic hypotension—which necessitates seeking immediate medical help. These documents mandate specific supportive procedures to manage this effect and prevent documented severe outcomes.

Therapeutic Uses of Enalapril Mylan

Main Therapeutic Uses

Enalapril Mylan belongs to a group of medicines known as angiotensin-converting enzyme (ACE) inhibitors. It is primarily used for the management of cardiovascular conditions where the regulation of blood pressure and heart function is necessary.

Hypertension

The primary use of this medication is the treatment of high blood pressure (hypertension). By widening the blood vessels, it helps the blood flow more easily throughout the body, which reduces the pressure against the arterial walls.

Heart Failure

Enalapril Mylan is used to treat symptomatic heart failure. In this condition, the heart is unable to pump blood as effectively as it should. The medication helps by reducing the workload on the heart, which can improve its pumping efficiency and alleviate associated symptoms like shortness of breath and swelling.

Prevention of Symptomatic Heart Failure

In patients who have weakened heart function but do not yet show outward symptoms of heart failure (asymptomatic left ventricular dysfunction), this medication may be prescribed to help prevent the development of symptomatic heart failure and reduce the risk of hospitalization.

Benefits and Clinical Goals

Blood Pressure Control: Helps maintain blood pressure within a healthier range, reducing the strain on the cardiovascular system.
Heart Protection: Assists in managing the long-term health of the heart muscle in patients with chronic cardiac conditions.
Symptom Management: Helps improve physical capacity and quality of life in patients with heart failure by making it easier for the heart to circulate blood.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility Rules

The eligibility for Enalapril Mylan is strictly defined by government regulatory documents, which establish clear rules for who may and may not use the medicine.

Classification	Population or Condition
Absolute Contraindication	History of angioedema related to any ACE inhibitor, hereditary/idiopathic angioedema, or hypersensitivity to the formulation.
Prohibited	Second and third trimesters of pregnancy. Use with aliskiren if the patient has diabetes mellitus or renal impairment (GFR le 60 mL/min/1.73 m^2).
Not Recommended	First trimester of pregnancy, neonates (under 1 month of age), and pediatric patients with a severe reduction in kidney function (GFR < 30 mL/min/1.73 m^2).

Conditional or Restricted Use

Use is established for adults and for children one month of age and older for hypertension. However, conditional use is required for several groups:

Organ Impairment: Patients with impaired renal function or hepatic impairment require dose adjustment or extreme caution.
Volume Depletion: Patients with volume or salt depletion (e.g., from diuretics) require close supervision.
Specific Comorbidities: Use requires caution in patients with conditions like renal artery stenosis or severe outflow tract obstruction of the heart.
Older Adults: The dose for older adults must be determined based on their kidney function.

What should I know about interactions with other medicines?

Enalapril is an Angiotensin-Converting Enzyme (ACE) inhibitor whose interaction profile is primarily defined by the risk of severe hypotension, hyperkalemia (high potassium levels), and angioedema (serious swelling). The following medicinal products, or classes of products, have documented interactions requiring specific precautions, monitoring, or avoidance:

Classification	Interacting Agents/Classes	Interaction Constraint
Contraindicated Combinations	Neprilysin Inhibitors (e.g., sacubitril/valsartan)	A 36-hour wash-out period must separate use.
	Direct Renin Inhibitors (e.g., aliskiren)	Avoid in patients with diabetes or moderate-to-severe kidney impairment (GFR <60 mL/min/1.73 m^2).
High-Risk Interactions	Potassium-Sparing Diuretics (e.g., amiloride, spironolactone, triamterene), Potassium Supplements, Salt Substitutes	Increases risk of hyperkalemia; generally not recommended or requires frequent monitoring.
	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors	May reduce the antihypertensive effect and increase the risk of worsening kidney function.
	Lithium	May increase lithium toxicity by reducing its clearance; frequent monitoring of lithium levels is required.
	Other Antihypertensive Agents, Alcohol, Tricyclic Antidepressants, Anaesthetics	Increases the risk of excessive hypotension (low blood pressure).
	Racecadotril	Increases the risk of angioedema.

Mechanism of Action

Enalapril is a pharmacologically inactive prodrug that undergoes complete hydrolysis, primarily in the hepatic tissue, to its active metabolite, enalaprilat. Enalaprilat functions as a competitive inhibitor of the angiotensin-converting enzyme (ACE), a peptidyl dipeptidase. This interaction occurs with the zinc ion in the active site of ACE, hindering the enzyme's catalytic conversion of angiotensin I to the potent vasoconstrictor, angiotensin II.

The resulting decrease in circulating and tissue-localized angiotensin II concentration removes the positive regulation on aldosterone secretion from the adrenal cortex and reduces direct agonism at angiotensin type 1 (AT1) receptors on vascular smooth muscle. Downstream, this pathway modulation results in systemic arteriolar and venous vasodilation and diminished renal sodium and water reabsorption. Furthermore, enalaprilat's inhibition of ACE, which is identical to kininase II, impedes the enzymatic degradation of the endogenous vasodilator bradykinin, contributing to the overall system-level physiological consequence of modulated peripheral vascular resistance.

Dosage and Administration Information

How to Use Enalapril Mylan

The usage of Enalapril Mylan (enalapril maleate) tablets follows a structured protocol focusing on the appropriate route, standardized dose ranges, and titration schedules. As a tablet formulation, the medicine is for oral administration and may be taken with or without food, establishing a routine for daily intake.

The frequency of use is determined by the specific condition being managed. For hypertension, the medicine is typically administered once daily. In contrast, the regimen for heart failure often involves twice-daily divided dosing to maintain a consistent effect.

Official Dosing Regimens

Indication	Initial Adult Dose	Maintenance Dose Range	Maximum Daily Dose
Hypertension	5 mg once daily	10 mg to 40 mg daily	40 mg
Heart Failure	2.5 mg once or twice daily	Titrated up to 20 mg daily	40 mg

Administration Principles

The treatment protocol for heart failure begins with a low initial dose (2.5 mg) and involves gradual dose titration over two to four weeks under medical supervision. Furthermore, specific dose adjustments are utilized for certain patient populations. For patients with renal impairment (kidney dysfunction), the initial dose is reduced to 2.5 mg once daily. The medicine is used as long-term therapy for the sustained management of chronic conditions, with the full therapeutic effect sometimes requiring several weeks of continuous use.

Handling Missed Doses

If a dose is missed, it is generally taken as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped.

Recent Clinical Evidence

Research evidence / Overview of studies for Enalapril Mylan

Evidence for use in Chronic High Blood Pressure

Enalapril Mylan was studied in the context of high blood pressure, a condition monitored by tracking systolic and diastolic measurements. The research base includes large-scale Randomized Controlled Trials (RCTs) and studies that examined the study medicine in comparison to other agents used in research settings. Findings describe patterns observed in the study populations, including the blood pressure measurements recorded in those receiving the study medicine compared to control groups.

Evidence for use in Symptomatic Heart Failure

The evidence for the use of Enalapril Mylan in people with symptomatic heart failure comes from landmark, multi-center, long-term Randomized Controlled Trials (RCTs). The main outcomes observed in these trials related to functional imbalance and included all-cause and cardiovascular mortality, as well as the frequency of hospital visits related to the cardiovascular system. Studies monitored the effect of different doses on the primary outcomes, finding that different doses sometimes resulted in similar measurements for the main endpoints studied.

Evidence for use in Asymptomatic Left Ventricular Dysfunction

Research on Enalapril Mylan in the context of research for asymptomatic left ventricular dysfunction was conducted using large-scale Randomized Controlled Trials (RCTs) designed to track prevention outcomes over extended periods. Researchers examined outcomes related to systemic or functional imbalance by measuring the time until patients progressed from an asymptomatic state to developing overt, symptomatic heart failure.

Evidence for use in Support of Renal Function

Enalapril Mylan was studied in patient groups defined by risk factors, such as those with diabetic nephropathy or other forms of chronic renal failure. Key outcomes examined included physiological measurements such as levels of albuminuria (protein in urine) and the rate of decline in the Glomerular Filtration Rate (GFR), which is a measurement of kidney function.

Research Gaps and Areas of Uncertainty

The research provides context but not individual predictions, and several areas of uncertainty remain. Limited information for long-term outcomes is available for certain uses, and comparative evidence is lacking in some areas against the newest standard-of-care treatments. Follow-up durations were limited in some smaller comparative studies, and findings were mixed regarding specific endpoints. The evidence highlights what is known—and what is still uncertain.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Enalapril Mylan (FAQ)

Q: Is a metallic taste in the mouth listed as a side effect?

A: Official safety documents list a potential side effect referred to as taste disturbance or dysgeusia. This effect is generally considered Uncommon, meaning it is reported in less than 1 in 100 people but more than 1 in 1,000. This information is found in regulatory safety data summaries.

Q: Are there official descriptions of how to manage the common cough side effect?

A: Regulatory labels state that the dry, persistent cough is a known and expected adverse reaction associated with the ACE inhibitor class of medicines. Regulatory documents describe the risk of cough and note it usually resolves after stopping treatment, but they do not contain specific guidance for managing this side effect while the medicine is continued.

Q: Can taking Enalapril Mylan cause skin rash?

A: Yes, official safety data indicates that a rash is a commonly reported adverse reaction. This is seen in less than 1 in 10, but more than 1 in 100 people taking the medicine. Regulatory documents also note that serious, though rare, skin reactions are among the documented safety warnings.

Q: How quickly does Enalapril Mylan start to work after I begin taking it?

A: According to official clinical pharmacology data, the active form of the medicine, enalaprilat, reaches its highest concentration in the bloodstream approximately three to four hours after an oral dose. The main effect of lowering blood pressure is typically maximal within four to eight hours of taking the tablet.

Q: What is the expected timeframe to notice the effects of Enalapril Mylan?

A: While the initial dose begins working quickly, achieving the full, sustained therapeutic effect for chronic conditions like high blood pressure or heart failure may take time. Official sources indicate that reaching maximum or desired effectiveness can require several weeks of continuous use.

Q: Is it common to feel tired when starting Enalapril Mylan?

A: Fatigue (tiredness) and asthenia (weakness) are listed as either Common or Very Common side effects in regulatory documents. Furthermore, hypotension (low blood pressure), which can cause dizziness and tiredness, is noted in official warnings as being most likely to occur at the initiation of treatment.

Q: Is it normal to have dizziness when first standing up while taking Enalapril Mylan?

A: Official warnings note that symptomatic hypotension (low blood pressure), which can cause dizziness, is a documented effect of the medicine. This effect is noted in official warnings as being most likely to occur at the initiation of treatment.

Q: Does this drug need to be taken at a specific time of day?

A: Official usage instructions indicate the tablet is for once-daily administration for hypertension and may be taken with or without food. Regulatory materials do not specify a mandatory time of day for the dose, but the frequency is defined by the treating clinician.

Q: What is the distinction between Enalapril and its active metabolite, enalaprilat?

A: Enalapril is officially classified as a prodrug, meaning it is inactive when taken. After ingestion, it is converted by the liver into its active form, enalaprilat. It is enalaprilat that performs the function of blocking the ACE enzyme to achieve the medicine's therapeutic effect.

Q: What are the typical non-serious side effects of Enalapril Mylan?

A: The most frequently documented effects, listed as Very Common or Common in official sources, include cough, headache, dizziness, fatigue, nausea, and diarrhoea. These are the most likely effects a person may observe while using the medicine.

Q: Is Enalapril Mylan the same as just 'Enalapril'?

A: Enalapril is the active ingredient within the medicine, officially known as enalapril maleate. Enalapril Mylan is the specific finished product marketed by the manufacturer Mylan. Regulatory bodies treat generic products, such as Enalapril Mylan, as bioequivalent to the original brand-name version, meaning they contain the same active ingredient and work in the same way.

Q: Does Enalapril Mylan cure high blood pressure or just manage it?

A: Official indications describe the medicine as being used for the treatment and management of high blood pressure and heart failure. Regulatory documents do not classify the medicine as a cure for either condition, but rather as an ongoing therapy to help control and sustain these chronic states.

Q: How long does Enalapril Mylan stay in the body?

A: Official clinical pharmacology data notes that the active form, enalaprilat, has an effective half-life of approximately 11 hours. This prolonged duration is due to the way it binds to the ACE enzyme, supporting its use in once or twice daily regimens.

Q: Are there any specific foods or drinks to avoid while on Enalapril Mylan?

A: Regulatory guidance on drug interactions focuses on products that increase the risk of high potassium levels (hyperkalaemia), such as salt substitutes that contain potassium. Separately, official data specifies that general food intake does not interfere with the medicine's absorption.

Q: Can Enalapril Mylan be taken with supplements or herbal remedies?

A: Official documents describe that potential interactions exist with products that affect blood pressure or potassium levels, which necessitates careful consideration based on the specific supplement or remedy. These interactions may include those found in certain herbal remedies or supplements.

Q: What is the difference between Enalapril Mylan and other brand names for Enalapril?

A: Enalapril Mylan is a generic version of the active ingredient, Enalapril maleate. Official regulatory bodies consider generic medicines to be bioequivalent to the original brand-name product. This means they are required to have the same quality, strength, stability, and intended use as the original branded product.

Q: Do I need to have regular blood tests while using Enalapril Mylan?

A: Official guidance includes recommendations for regular monitoring of specific physiological measurements. These typically include tests for serum potassium levels and kidney function (creatinine), especially when treatment is first started and in individuals who have pre-existing risk factors.

Q: What happens if I stop taking Enalapril Mylan suddenly?

A: Regulatory documents describe the medicine as being used for long-term therapy for the sustained management of chronic conditions. Discontinuation of chronic blood pressure treatments may result in the underlying condition returning or progressing, but there are no specific regulatory warnings about discontinuation effects.

Q: Do official documents mention Enalapril Mylan's effect on blood sugar levels?

A: Official regulatory information notes that this medicine may lower blood glucose levels. If an individual has diabetes and is taking antidiabetic medication, close monitoring of blood glucose levels is a consideration mentioned in the official guidance.

Q: Can the effectiveness of Enalapril Mylan change over time?

A: Official documents note that in some patients taking the medicine once daily, the blood pressure lowering effect (antihypertensive effect) may decrease toward the end of the 24-hour dosing interval. This potential change in effectiveness is a factor in determining the appropriate dosing frequency.

Q: Are there specific ethnic or population groups where Enalapril Mylan effects might differ?

A: Clinical trial evidence summarized in regulatory dossiers suggests that the blood pressure lowering effect of ACE inhibitors tends to be less pronounced in patients of African ancestry compared to non-Black patients. This finding is based on observed patterns within study populations.

Q: What research says about Enalapril Mylan's use in children?

A: Official labels and documents confirm the medicine has been studied in pediatric patients, specifically children one month of age and older, for the management of hypertension. Its use in this age group is established based on the evidence collected during these official trials.

Q: Is Enalapril Mylan a type of water pill?

A: Enalapril is officially classified as an ACE inhibitor, which is a distinct pharmacological class. While its mechanism does include effects on sodium and water reabsorption in the kidney, it is chemically and functionally different from a diuretic, which is commonly referred to as a 'water pill'.

Q: Do people typically take Enalapril Mylan for life?

A: Official usage instructions describe the medicine as being used as long-term therapy for the sustained management of chronic conditions like heart failure and high blood pressure. Treatment duration is determined by the managing health professional based on the specific chronic condition being addressed.

Q: Does Enalapril Mylan affect the body's fluid balance?

A: Yes, the medicine's official mechanism of action involves modulating the body's fluid and blood pressure system. It is known to lead to diminished renal sodium and water reabsorption in the kidneys, thereby affecting the body’s overall fluid regulation.

How should Enalapril Mylan be stored and disposed of?

The storage and disposal of enalapril maleate tablets are defined by regulatory standards to protect the medicine's stability and ensure safety.

Mandatory Storage Conditions

Labeled Requirement	Official Statement from Regulatory Documents
Storage Temperature:	Store at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature).
Protection Requirements:	The container must be kept tightly closed and the product must be protected from moisture.
Prohibited Environments:	Do not freeze and avoid exposure to excessive heat or high-humidity areas, such as a bathroom.
Child Safety:	The medicine must be kept out of the reach of children.

Official Disposal Protocol

Official disposal instructions state that unused or expired medicine must be safely discarded. Patients are instructed not to flush the tablets down a toilet or pour them down a drain unless specifically advised to do so, and should follow local disposal regulations or drug take-back programs.

Enalapril Mylan